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Introduction
Vitiligo is a chronic auto-inflammatory depigmenting skin disorder associated with psychosocial morbidity. 1 The prevalence of vitiligo ranges from 0.05% to 2.0% globally, with considerable regional variation. 2, 3 Vitiligo has a complex bidirectional relationship with mental health (MH) disturbances. Vitiligo has been found to be commonly triggered by antecedent psychological triggers. 4 In addition, vitiligo has been found to negatively impact upon multiple aspects of quality of life (QOL) in children and adults, including self-consciousness, difficulty with relationships, school and work, and clothing choices. 5-7 Vitiligo patients endure a higher level of distress compared to the general population and routinely are faced with a negative social stigma leading to an avoidance of activities. 8 The increased psychosocial morbidity of vitiligo might acutely lead to or trigger symptoms of depression, suicidality, anxiety and other MH symptoms. However, little is known about the relationship between vitiligo and MH emergencies. We hypothesized that vitiligo is associated with higher rates of hospitalization for MH emergencies. In addition, hospitalizations for MH emergencies can be prolonged and costly. 9 We hypothesized that vitiligo is associated with substantial excess costs indirectly related to MH hospitalizations.
In the present study, we examined the associations of vitiligo and MH hospitalizations in the United States.
Methods

Data source
We analysed data from the 2002 to 2012 Nationwide Inpatient Sample (NIS) provided by the Healthcare Cost and Utilization Project (HCUP) from the Agency for Healthcare Research and Quality (AHRQ). Each year of NIS contains an approximately 20% stratified representative sample of all inpatient hospitalizations in the United States. Sample weights were created by NIS that factored the complex sampling design of US hospitals and allowed for representative estimates of discharges across the whole country. All data were de-identified, and no attempts were made to identify any of the individuals in the database. All parties with access to the HCUP were compliant to HCUP's formal data use agreement. The study was approved by the institutional review board at Northwestern University.
Identification of vitiligo and mental health comorbidities
The NIS lists only one primary diagnosis and up to 24 secondary diagnoses. Per HCUP inpatient database standards, the first listed diagnosis is the principal diagnosis, that is the primary reason for hospitalization. The databases were searched for a primary or secondary diagnosis of vitiligo using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 709.01. The control group included all patients without any diagnosis of vitiligo, excluding live births and normal pregnancies, yielding a representative cohort of hospitalized patients in the US. Mental health comorbidities were pre-coded according to AHRQ comorbidity measures and through the NIS Clinical Classification Software (CCS). Comorbidities pre-coded by the AHRQ also utilized Diagnosis-Related Groups (DRG) and thus would capture a higher frequency of the comorbidities compared to the use of ICD-9-CM codes alone. Admission for a MH emergency was identified by a primary diagnosis of the disorder. The MH disorders included mood disorders (including bipolar disorder and depression), anxiety, suicidality, substance abuse, alcohol abuse, attention-deficit (hyperactivity) disorder (ADD/ ADHD), psychotic disorders (including schizophrenia), cognitive, developmental, adjustment, impulse, personality, paediatric, history of MH disorders and other MH disorders. A variety of ICD-9-CM codes for mental health disorders, including those for alcohol abuse, depression, 10 schizophrenia, 11 suicide attempt, substance abuse, 12 psychosis, bipolar disorder and affective disorders, 13 has been found to have strong positive predictive value for their use in epidemiological studies. The codes used to create these variables are presented in Table S1 . A composite variable was created for any MH disorder.
Data processing and statistical analysis
All data were processed using SAS 9.4 (SAS Institute, Cary, NC, USA). Survey procedures were implemented in the analysis to look at individual hospitalization. All statistical models consisted of discharge trend weights, clustering by individual hospitals, and sample strata which accounted for each individual year, hospital's census region or division, ownership and control, location and teaching status, and bed size, which were all provided by the NIS. Baseline characteristics analyses were performed, and survey-weighted binary logistic regression models were crafted to assess the association of vitiligo with mental health comorbidities. The independent variable was a diagnosis of vitiligo, and the dependent variable was having a diagnosis of mental health disorder vs. no mental health disorder. Multivariate logistic regression models controlling for age (continuous), sex (male/female), race (white/non-white) and insurance status (insured/ non-insured) were implemented. Selection models for predictors of hospitalization for any mental health disorder along with inpatient mortality among patients with vitiligo were also created. Crude and adjusted odds ratios (cOR and aOR, respectively), 95% confidence intervals (CIs) and P-values were determined. A two-sided P < 0.05 was considered statistically significant for all statistical processes. Weighted frequency and weighted prevalence of inpatient mortality were determined. Mean and total cost of hospitalization were assessed, and similar analyses were performed for length of hospitalization. Complete case analysis was performed. A two-sided P-value <0.05 was taken to indicate statistical significance for all estimates. The prevalence of having MH disorders was determined in children and adults with or without vitiligo. Baseline characteristics of patient subsets were determined. To examine the associations of vitiligo with admission for MH comorbidities, multivariable logistic regression models adjusting for age, sex, race/ethnicity and insurance type were constructed with each of the MH comorbidities as the dependent variables. Adjusted odds ratios (aOR) and 95% confidence intervals (CI) were estimated. aOR and 95% CI were presented in Forest plots using OpenMeta Analyst, an open-source software supported by Brown University and the AHRQ. Summary statistics were determined for length of stay (LOS) and cost of inpatient care, including total and geometric mean (95% CI). To determine the predictors of hospitalization, surveyweighted multivariable logistic regression models were constructed with hospitalization for MH disorders as the dependent variable and vitiligo as the independent variable. To determine the predictors of cost of care and LOS, multivariable linear regression models were constructed with log-transformed cost of care and LOS as the dependent variables. Cost of care and LOS were log- Figure 1 Association between vitiligo and hospitalization for mental health disorders. Survey logistic regression models were constructed with vitiligo as the independent variable and hospitalization for the respective mental health disorders as the dependent variable. Models included age, sex, race/ethnicity and insurance status as covariates. Adjusted odds ratios and 95% confidence intervals were estimated. Forest plots of adjusted odds ratios and 95% CIs are presented. ADD/ADHD, attention-deficit disorder/attention-deficit hyperactivity disorder.
transformed because they were not normally distributed. Other independent variables included age (0-4/5-10/11-17/18-39/40-59/60-79/≥80 years), gender (male/female), race/ethnicity (white/ black/Hispanic/Asian/Native American/other), mean annual income of the hospital zip-code (quartiles), health insurance coverage (yes/no; Medicare/Medicaid/private/self-pay/no charge/ other) number of chronic conditions (0-1/2-5/≥6), season of admission (winter/spring/summer/autumn), and hospital location (metropolitan/fringe-metropolitan/micropolitan/not metropolitan or micropolitan; Northeast/Midwest/South/West) and admission year. Multivariable logistic regression models used stepwise selection from the above-mentioned covariates (alpha < 0.1).
Results
Baseline characteristics
Overall, 87 053 155 hospital admissions were captured in the NIS between years 2002 and 2012, with 11 573 admissions with a diagnosis of vitiligo (450 in children and 11 123 in adults). Among the cases of vitiligo, 45.1% were female, 44.8% were white and 92.5% were insured, with a mean AE SD age of admission of 55.89 AE 19.28 years (Table 1) .
Hospitalization for mental health disorders
Among patients with vitiligo, 483 (4.17%) were primarily admitted for a mental health disorder, while 3181 (27.49%) had a secondary mental health disorder diagnosis upon admission. In contrast, 1 896 928 (2.18%) patients without vitiligo were primarily admitted for a MH disorder and 15 354 322 (17.64%) had a secondary mental health disorder diagnosis at time of hospitalization.
In multivariable survey-weighted logistic regression models controlling for age, sex, race/ethnicity and insurance type, vitiligo was associated with admission for any MH disorder [aOR (95% CI): 1.69 (1.61-1.78); Fig. 1 ]. In particular, vitiligo was associated with 14 of the 15 MH disorders examined, including anxiety, schizophrenia, depression, suicidal risk, personality disorder, ADD/ADHD and conduct disorder, substance use disorder, childhood and adolescent psychiatric illnesses, alcoholrelated disorders, adjustment disorders, developmental disorders, impulse control disorders, history of mental health disorders and miscellaneous mental health disorders (P < 0.01 for all). Of the mental health comorbidities investigated, vitiligo was not significantly associated with cognitive disorders (P = 0.60; Fig. 1 ). Table 2 ].
Associations of hospitalization for mental health disorders
Cost of care, LOS and inpatient mortality
Overall, patients who had vitiligo with vs. without any mental health disorder had prolonged LOS [5.6 (5.3-5.8] vs. 4.8 (4.6-4.9) days], with an excess of 5569 mean annual days of MH hospitalization attributed to vitiligo (Table 3) . In particular, patients with vs. without vitiligo had significantly increased LOS, including anxiety, schizophrenia, personality disorders, depression, substance-related disorders, suicide, history of mental health illnesses, alcohol-related disorders, adjustment disorder, cognitive disorders, developmental disorders and miscellaneous mental health disorders, but shorter LOS for ADD/ADHD and childhood mental health disorders.
Similarly, patients who had vitiligo with vs. without any mental health disorder had increased geometric-mean cost of inpatient care [$10 992 ($10 477-$11 507) vs. $10 082 ($9728-$10 435)], with an excess $10 479 897 of mean annual excess costs of MH hospitalization attributed to vitiligo. In particular, vitiligo was associated with excess costs for anxiety, personality, depression, ADD/ADHD, substance-related disorders, suicide, Table 3 Cost of care and length of stay (LOS) of hospitalization for mental health disorders in patients with vitiligo Mental health in vitiligo history of mental health disorders, adjustment disorders, cognitive disorders, developmental disorders and miscellaneous mental health disorders, but lower costs for schizophrenia, childhood mental health disorders and alcohol-related disorders.
Patients with vitiligo had similar inpatient mortality with vs. without a MH disorder (1.17% vs. 2.02%).
Discussion
The present study found strong associations between vitiligo and multiple MH disorders, including anxiety, depression, suicidal risk, personality disorder, substance and alcohol-related disorders. Factors associated with MH disorders in vitiligo patients were middle age, male sex, white race, government or no insurance, and increasing number of chronic conditions. MH disorders were associated with increased LOS and cost per hospitalization, but not inpatient mortality, in vitiligo patients. Vitiligo was associated with an excess $10 million cost of hospitalization for MH comorbidity. Taken together, the results of this study indicate that vitiligo is associated with substantially increased morbidity from MH disorders.
This study expands on previous studies that showed higher rates of MH disorders in persons with vitiligo compared to those without vitiligo. A meta-analysis study pooled data on 1080 patients with vitiligo and found that at least one in four vitiligo patients were diagnosed with a form of clinical depression when using a validated screening questionnaire.
14 A cross-sectional study of 150 patients with vitiligo reported high prevalences of depression (34%) and anxiety (60%). 15 A retrospective study of 31 adults with vitiligo found increased occurrence of 3+ uncontrollable events, decreased perceived social support and increased anxiety in vitiligo compared to 116 other dermatologic disease controls. 16 A cross-sectional study of 30 Indian patients with vitiligo found that 10% had thoughts of suicide, and 3.3% had attempted suicide. 17 A study of Egyptian adults, from ages 18 to 65, similarly found that 2% of vitiligo patients attempted suicide. 18 An uncontrolled study of Indian adults and children found that vitiligo patients with suicidal ideation were more likely to turn to alcohol as a coping mechanism. 19 A recent systematic review of 29 studies showed that other MH comorbidities for example adjustment disorder, substance disorder and alcohol abuse were evident in vitiligo patients. 20 The present study found that vitiligo was associated with primary hospitalization for virtually every MH disorder examined and was more likely to be hospitalized for suicidal risk, alcohol and substance abuse. In addition, vitiligo was associated with prolonged and more costly hospitalizations for MH disorders, with substantial excess costs indirectly conferred by comorbid MH disorders. We found the peak ages of hospitalization for MH disorders in vitiligo were 19-49 years. In contrast, a previous US population-based study found the peak prevalences of vitiligo occurred at ≥55 years of age. 21 It may be that vitiligo is more bothersome and associated with more MH comorbidity in younger patients, despite being more common in the elder population. Previous studies suggested that non-whites are more likely to face stigma related to vitiligo, as skin discoloration can be perceived as reflecting poor social status. 22 However, in the present study, whites with vitiligo had a higher odds of hospitalization for MH disorders. This suggests that vitiligo is also associated with substantial psychosocial burden even amongst whites. In addition, persons with vitiligo, who were insured with Medicare, Medicaid, or were uninsured, were more likely to be admitted for MH disorders. It may be that poor access to outpatient specialty care may lead to more severe vitiligo and consequently higher likelihood of MH disorders. The results of this study have clinical and public health significance. Vitiligo is commonly considered to be a purely cosmetic disorder with low direct costs of management. However, the present study demonstrates high prevalences of MH comorbidities and considerable excess indirect costs related to inpatient MH care in vitiligo patients. Vitiligo patients may benefit from increased screening for MH disorders and suicidal risk, with appropriate referral and management for MH care. In addition, more aggressive treatment of vitiligo may be required for patients with major psychosocial effects and MH comorbidity.
Strengths of this study include the use of a nationally representative sample of all US hospitalizations, with almost 90 million records and a large number of vitiligo cases. Limitations of the study include the inability to perform temporal analysis of comorbidities, lack of data on severity of vitiligo and MH comorbidities, or treatments used prior to and during hospitalization. In addition, the frequency of admissions with a diagnosis of vitiligo observed in NIS (0.013%) was lower than prevalence estimates in the US (0.5-2%). This may be because a diagnosis of vitiligo may not always be coded during a hospitalization for an acute or life-threatening disorder. Thus, estimates of excess cost in this study may underestimate the true costs of MH disorders in vitiligo.
In conclusion, vitiligo is associated with hospitalization for multiple MH disorders. Further studies are needed to confirm these associations, their underlying mechanisms and ideal strategies for their prevention and treatment.
